---
schema_version: "secwatch.filing_event.v1"
accession: "0000917520-23-000026"
form_type: "8-K"
ticker: "IART"
cik: "0000917520"
company_name: "INTEGRA LIFESCIENCES HOLDINGS CORP"
filed_at: "2023-04-26T23:59:59+00:00"
generated_at: "2026-06-16T15:05:00.450972+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Integra LifeSciences Q1 revenue $380.8M, organic growth 4.6%; adj EPS $0.74 flat YoY

## Summary
- Q1 revenues $380.8M, +1.1% reported, +4.6% organic vs Q1 2022.
- GAAP EPS $0.29 vs $0.39 prior year; adjusted EPS $0.74 flat.
- Codman Specialty Surgical $248.1M (+3.5% organic); Tissue Technologies $132.7M (+6.8% organic).
- Full-year 2023 guidance reaffirmed: revenue $1,602-1,620M, adj EPS $3.43-3.51.
- Initiated $150M accelerated share repurchase; amended credit facility extended to 2028.

## SEC filing metadata
- accession: 0000917520-23-000026
- form_type: 8-K
- ticker: IART
- cik: 0000917520
- company_name: INTEGRA LIFESCIENCES HOLDINGS CORP
- filed_at: 2023-04-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/917520/000091752023000026/0000917520-23-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/917520/000091752023000026/iart-20230426.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000917520-23-000026
- JSON: https://secwatch.observer/filing/0000917520-23-000026.json
- Plain text: https://secwatch.observer/filing/0000917520-23-000026.txt

## Key facts
- Earnings Releases
  INTEGRA LIFESCIENCES HOLDINGS CORP reported the first quarter ended March 31, 2023 results: revenue $380.8 million, net income $24.2 million, EPS $0.29 per diluted share. Guidance reaffirmed.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $380.8 million
  - Net income: $24.2 million
  - EPS: $0.29 per diluted share
  - Guidance: reaffirmed
  - Result: reported results
  source text: Total reported revenues of $380.8 million increased 1.1% on a reported basis and increased 4.6% on an organic basis compared to the prior year. The Company reported GAAP gross margin of 61.1%, compared to 62.1% in the first quarter of 2022. Adjusted gross margin was 67.3%, compared to 67.7% in the prior year. Adjusted EBITDA for the first quarter of 2023 was $92.3 million, or 24.2% of revenue, compared to $93.5 million million, or 24.8% of revenue, in the prior year. The Company reported GAAP net income of $24.2 million, or $0.29 per diluted share, in the first quarter of 2023, compared to a GAAP net income of $32.9 million, or $0.39 per diluted share, in the prior year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/917520/000091752023000026/0000917520-23-000026-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.